May 29, 2020
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology (EULAR 2020)
Dec 09, 2019
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting
Nov 10, 2019
Nektar Therapeutics Presents Data from First-in-Human Phase 1a Study on Novel T Regulatory Cell Stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology
Jun 13, 2019
First-in-Human Data Presented from Phase 1a Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology
Jun 11, 2019
Nektar Therapeutics to Host Webcast Conference Call with Immunology Expert for Analysts & Investors During 2019 European Congress of Rheumatology (EULAR 2019)
Apr 02, 2019
Nektar Therapeutics Presents Preclinical Data on its Immuno-Oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019
Feb 27, 2019
Nektar Therapeutics Announces Several Preclinical Data Presentations for its Immuno-oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019
Nov 09, 2018
Nektar Therapeutics Presents New Clinical and Preclinical Data for its Immuno-Oncology Pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nov 07, 2018
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - NKTR
May 16, 2018
Nektar Therapeutics Announces Six Abstracts Accepted for Presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 24, 2018
New Oncology Clinical Collaboration between Nektar and Takeda to Evaluate Combination of NKTR-214, a CD122-biased Agonist, and TAK-659, a Dual SYK and FLT-3 Inhibitor, in Liquid and Solid Tumors
Apr 15, 2018
Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2018
Apr 11, 2018
Nektar Announces Dosing of First Patient in Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 with CD122-Biased Agonist NKTR-214 in Patients with Advanced Solid Tumors
Nov 07, 2017
New Data Featuring Nektar Therapeutics' Wholly-Owned Immuno-Oncology Pipeline to be Presented at the 2017 Society for Immunotherapy of Cancer 32nd Annual Meeting
Sep 20, 2017
Nektar Therapeutics Announces Seven Abstracts Accepted for Presentation at 2017 Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting